Item 2.02. Results of Operation and Financial Condition
On August 14, 2019, Ritter Pharmaceuticals, Inc. (the "Company"), issued a press
release announcing the financial results for the three and six months ended June
30, 2019, entitled "Ritter Pharmaceuticals Reports Financial Results for the
Three and Six Months Ended June 30, 2019 and Provides a Corporate Update" (the
"Press Release"). A copy of the Press Release is furnished as Exhibit 99.1
hereto and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed filed for the purposes of Section 18 of the United
State Securities Exchange Act of 1934, as amended, or otherwise subject to the
liability of Section 18. Furthermore, the information shall not be deemed
incorporated by reference into any registration statement or any other filing
under the United States Securities Act of 1933, as amended, except as shall be
expressly set forth by specific references in such filings.
Item 9.01. Financial Statements and Exhibits
Exhibit No. Description
99.1 Press Release dated August 14, 2019, entitled "Ritter
Pharmaceuticals Reports Financial Results for the Three and Six
Months Ended June 30, 2019 and Provides a Corporate Update"
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RITTER PHARMACEUTICALS, INC.
By: /s/ Andrew J. RitterName: Andrew J. Ritter
Title: Chief Executive Officer
Date: August 14, 2019
© Edgar Online, source Glimpses